New blood thinner CG-0255 faces off against plavix in early trial
NCT ID NCT07619885
First seen Jun 08, 2026 · Last updated Jun 21, 2026 · Updated 4 times
Summary
This Phase 1 study compares a new investigational drug, CG-0255, to the standard blood thinner Plavix in 136 healthy adults aged 18-55. The goal is to see how the body absorbs and processes each drug and how well they prevent blood clotting. Participants will receive either CG-0255 (as an injection or capsule) or Plavix (as a pill) and have their blood tested over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Syneos Health
RECRUITINGMiami, Florida, 33101, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CG-0255 besylate (a prodrug similar to clopidogrel/Plavix)
What this could lead to
If successful, this could lead to a new anti-clotting drug option for people with heart conditions or stroke risk.
What could go wrong
This is an early Phase 1 study in healthy people, not patients. It only measures drug levels and platelet activity, not actual clinical outcomes like heart attacks. The drug may not work better or may have unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.